The results of this study showed that enalapril could reduce the expression of TLR2 and NF-κB protein; reduce the level of inflammatory factors such as NT-proBNP, TNF-α, and MMP-9, and inhibit the inflammatory response of CHF rabbits, thereby delaying the abnormal remodeling of the myocardial interstitium and ultimately protecting the cardiac function, which are consistent with partial research results of Lee and Kim et al. [17, 18]. This evidence concerns the gene NFKB1 and congestive heart failure.